Lugano, Switzerland, 20 February 2024 – The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care. This event brings together various experts in the early drug development arena, including investigators from academia, investor and regulatory bodies, as well as translational scientists.
The event will be held in Paris, France, between 26-28 February.
New this year
-
Four new special sessions will enrich this year’s scientific programme, with international speakers from the pharmaceutical industry addressing methodological and regulatory challenges in the development and implementation of innovative cancer therapeutics.
Related content: Session on 26 February, 13:45-15:15 CET; Sessions on 27 February, 11:15-12:45 CET and 13:45-15:15 CET; Session on 28 February, 13:30-15:00 CET
Programme highlights
-
The role of artificial intelligence, machine learning, and digital technology in early phase research: From uncovering new immunotherapy targets with clinical potential to unveiling new potential targeted therapies
Related content: 1O, 2P, 4P, 5P and session on 27 February, 8:00-8:45 CET -
Novel perspectives on antibody-drug conjugates: new targets, linkers, payloads and combination with other agents
Related content: Session on 28 February, 09:15-10:45 CET -
ctDNA as promising biomarker to predict the patients’ response to treatment and guide experimental therapeutics in phase I trials
Related content: 85O, 86O, Session on 27 February, 09:15-10:45 CET
Award keynote lectures
-
“Implementing precision oncology: From genomics to ADCs” by Funda Meric-Bernstam, recipient of the 2024 TAT Honorary Award, 26 February 2024, 13:00-13:40 CET
-
“Revisiting the neoantigen approach for cancer immunotherapy”, by Yardena Samuels 27 February 2024, 08:45-09:15 CET
The results of more than 110 studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Friday, 23 February. Please be kindly informed that onsite press accreditation will not be available.
Further information
ESMO Press Office
press@esmo.org
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO TAT 2024 and the official congress hashtag #ESMOTAT24. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Instagram, Facebook
About the European Society for Medical Oncology (ESMO)
Representing more than 35,000 oncology professionals from 172 countries worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org